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The pan-histone deacetylase (HDAC) inhibitor, trichostatin A,
was found to reduce cyst progression and slow the decline of
kidney function in Pkd2 knockout mice, model of autosomal
dominant polycystic kidney disease (ADPKD). Here we
determine whether HDAC inhibition acts by regulating cell
proliferation to prevent cyst formation, or by other
mechanisms. The loss of Pkd1 caused an upregulation of the
inhibitor of differentiation 2 (Id2), a transcription regulator,
triggering an Id2-mediated downregulation of p21 in mutant
mouse embryonic kidney cells in vitro. Using mouse
embryonic kidney cells, mutant for Pkd1, we found that
trichostatin A decreased Id2, which resulted in upregulation
of p21. Further, phosphorylated retinoblastoma (Rb), usually
regulated by Cdk2/Cdk4 activity, was also reduced in these
cells. Since these latter enzymes are under the control of p21,
these studies suggest that the proliferation of cyst epithelial
cells that is reduced by trichostatin A might result from p21
upregulation, or alternatively through the Rb-E2F pathway.
Additional studies showed that Id2 directly bound to Rb,
releasing the transcription activator E2F from
transcriptionally inactive Rb-E2F complexes. HDAC inhibition
was able to reverse this process by downregulation of Id2.
Furthermore, treatment of pregnant Pkd1 mice with
trichostatin A prevented cyst formation in the developing
embryonic kidneys, showing that this inhibition is effective
in vivo during early cyst formation. Thus, HDAC inhibition
targets Id2-mediated pathways to downregulate cystic
epithelial cell proliferation and hence cystogenesis.
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Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common hereditary disorders in humans,
affecting 1 in 500–1000 in the United States.1 The hallmark of
the disease is the development of multiple bilateral renal
cysts that replace the normal renal parenchyma, resulting in
end-stage renal disease inB50% of individuals with ADPKD.
Cyst formation is thought to start early in kidney development
and continue throughout the life of the affected individual.
Most cases of ADPKD are caused by mutations in one of two
genes: PKD1, accounting for 85–95% of the cases, and PKD2,
accounting for most of the remainder.2 The gene product
of PKD2, polycystin-2 (PC2), either alone or in complex
with the gene product of PKD1, polycystin-1 (PC1), appears
to function as a calcium-permeable cation channel.3–6 The
unexpected association of the primary cilium with several
inherited cystic kidney diseases and localization of cysto-
proteins including PC1 and PC2 to cilia has led to the
‘primary cilia’ hypothesis. Simply stated, the hypothesis is that
structural or functional abnormalities in the primary apical
cilia of tubular epithelia have a role in renal cyst development
and may represent a unifying mechanism of cyst formation.
In addition to well-characterized genetic abnormalities
that lead to cyst initiation and progression, it is now
recognized that epigenetic regulators may also have a
significant role in cystogenesis. It has been shown recently
that histone deacetylases (HDACs) may be promising targets
for ADPKD treatment.7,8 It has been found that inhibiting
HDACs either by a class I HDAC inhibitor, valproic acid, or
by a pan-HDAC inhibitor, trichostatin A (TSA), reduces the
cyst progression and slows the decline of kidney function in
Pkd1 and Pkd2 knockout mice. However, the underlying
mechanisms remain to be clarified.
HDACs regulate cellular functions either through deace-
tylation of histones or nonhistone transcription factors.9–12
In addition to the more global effects of HDACs on gene
expression through deacetylation of histones, HDACs may
also affect unique pathways through specific HDAC-targeted
proteins to regulate specific cellular processes. In this study,
we report that HDAC inhibition (HDACi) targets inhibitor of
differentiation 2 (Id2), thus affecting Id2-mediated p21 and
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Rb–E2F pathways to regulate cystic epithelial cell prolifera-
tion. We have found that loss of Pkd1 leads to upregulation
of Id2, and that HDACi decreases Id2 levels, causing
upregulation of p21 in Pkd1 mutant cells. HDACi also
decreased the levels of phosphorylated retinoblastoma (Rb),
which was regulated by p21-mediated Cdk2/Cdk4 activity,
suggesting that the upregulated p21 might work through the
Rb–E2F pathway to inhibit cystic epithelial cell proliferation.
Id2 was also found to function by directly binding and
sequestering Rb, thus releasing E2F from Rb–E2F complexes,
and that HDACi was able to reverse this process. Treatment
with TSA delayed cell cycle reentry in Pkd1 mutant mouse
embryonic kidney (MEK) cells. Furthermore, treatment of
pregnant mice with TSA prevented cyst formation in Pkd1
mutant embryonic kidneys, demonstrating that HDACi is
effective during early cyst development. These findings
suggest that HDACi is a potential therapeutic approach for
treating ADPKD.
RESULTS
HDACi reduces S-phase entry of Pkd1 mutant MEK cells
Although it has been recognized recently that HDACs may be
useful targets for ADPKD treatment,7,8 the underlying
mechanisms are unclear. Previous studies using inhibitors
of HDACs in cancer cells indicated that these compounds
reduce cell proliferation. Therefore, we examined whether
addition of the HDAC inhibitor TSA to MEK cells produced
any effect on cell proliferation. We found that TSA-treated
(100 ng/ml) Pkd1 mutant (Pkd1null/null) MEK cells prolifer-
ated B60% slower than nontreated Pkd1null/null MEK cells.
We also found that inhibition of HDACs with TSA was
cell cycle dependent (Table 1). By fluorescence-activated cell
sorting analysis, we could show that about 62%, 29%, and
9% of the TSA-treated Pkd1null/null MEK cells were in G1, S,
and G2 phases, respectively. By contrast, about 43%, 47%,
and 9% of the control (untreated) Pkd1null/null MEK cells
were in G1, S, and G2 phases, respectively. The cell cycle
profile of the TSA-treated Pkd1null/null MEK cells was similar
to that of the wild-type MEK cells in that about 67%, 27%,
and 6% of the wild-type cells were in G1, S, and G2 phases,
respectively. The differences of the cells in G0/G1 and in
S-phase between the Pkd1 mutant MEK cells and the cells
including Pkd1 mutant MEK cells treated with TSA and Pkd1
wild-type MEK cells treated with or without TSA were
statistically significant (Po0.05), which suggested that TSA
treatment might restore the cell cycle profile of Pkd1null/null
MEK cells by decreasing S-phase entry.
HDACi decreases expression of Id2 and increases expression
of p21 in Pkd1 mutant MEK cells
Expression of the key cell cycle regulator p21 has been shown
to be decreased in Pkd1 mutant MEK cells and Pkd1 mutant
mouse kidneys.13,14 We found that treatment with TSA
increased the expression of p21 in Pkd1null/null MEK cells to
the levels seen in Pkd1 wild-type MEK cells (treated or
untreated with TSA; Po0.01; Figure 1a). To determine the
potential mechanisms for this increased expression of p21 in
response to TSA treatment, we examined the expression of
Id2 and HDAC1, two key regulators of p21 transcription, in
other cells.15,16 We found that Id2 expression was upregulated
in Pkd1null/null MEK cells and that TSA treatment decreased
the expression of Id2 in these cells to the levels seen in
Pkd1 wild-type MEK cells (Po0.001; Figure 1a). In contrast,
the expression levels of HDAC1 were not affected by
TSA treatment (Figure 1a). In addition, the levels of Id2
in Pkd1null/null MEK cells over a number of hours after
treatment with TSA gradually decreased, over the same
time the levels of p21 increased (Figure 1b). These results
suggested that TSA might regulate the expression of p21
through Id2.
Id2, but not HDAC1, regulates the expression of p21 in
Pkd1null/null MEK cells
To determine whether the expression of p21 is regulated by
Id2 in Pkd1 mutant MEK cells, Id2 was knocked down with
small interfering RNA (siRNA) and p21 expression was
examined. We found that inhibition of Id2 by siRNA led to
increased p21 expression (Po0.01; Figure 2a).
Although HDAC1 expression did not appear to be affected
by TSA treatment, TSA might still affect HDAC1 function or
activity. To test this possibility, we examined binding of
HDAC1 to the p21 promoter by chromatin immunoprecip-
itation. As shown in Figure 2b, we found that HDAC1 bound
to the p21 promoter in both Pkd1 wild-type and Pkd1null/null
MEK cells. Although we observed that binding
of HDAC1 to the p21 promoter was decreased in Pkd1
wild-type MEK cells treated with TSA, the expression levels
of p21 were not changed (Figure 1a). In addition, inhibition
of HDAC1 with siRNA did not lead to activation of p21
expression (Figure 2c). These results suggest that HDACi
through targeting Id2, but not HDAC1, regulates the
expression of p21 in wild-type and Pkd1null/null MEK cells.
TSA affects the Rb–E2F1 pathway
Fluorescence-activated cell sorting analysis suggested that
S-phase entry is significantly increased in Pkd1 mutant MEK
cells and that TSA treatment decreases this S-phase entry
Table 1 | TSA treatment decreased S-phase entry of Pkd1
mutant MEK cells
Pkd1 G0/G1 phase (%) S phase (%) G2 phase (%)
WT 66.7±8.4 27.3±5.5 6.0±3.1
WT-TSA 66.7±5.9 28.3±7.3 4.7±1.3
Null 42.7±2.9 47.3±5.3 9.0±2.9
Null-TSA 61.7±3.0 29.0±1.7 9.3±1.3
Abbreviations: FACS, fluorescence-activated cell sorting; MEK, mouse embryonic
kidney; TSA, trichostatin A; WT, wild type.
Data present mean±s.e. calculated from three independent FACS analyses.
The differences of the cells in G0/G1 and in S-phase between the Pkd1 mutant MEK
cells (null cells) and the other cells, which including Pkd1 WT MEK cells treated with
or without TSA and Pkd1 mutant MEK cells treated with TSA, were statistically
significant (Po0.05). In particular, the S-phase entry of Pkd1 mutant MEK cells (null
cells) were significantly increased compared with other cells, whereas TSA treatment
significantly decreased S-phase entry of Pkd1 mutant MEK cells (Po0.01).
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(Table 1), thus slowing cell proliferation. Id2 has been found
to stimulate cell proliferation by two mechanisms: (1) by
direct binding to Rb and (2) by downregulation of p21,
resulting in increased Rb phosphorylation. In both cases,
Rb is released from the Rb–E2F complex, allowing E2F
to activate target cell cycle genes.15 We found that Rb,
phospho-Rb, and E2F1 were upregulated in Pkd1null/null MEK
cells compared with wild-type cells (Figure 3a). We also
found that TSA significantly decreased expression of
phospho-Rb (Po0.01; Figure 3a, bottom panel), but only
slightly decreased expression of Rb and E2F1 in Pkd1null/null
MEK cells (Figure 3a). We next examined the inter-
actions between Id2 and Rb and between Rb and E2F1 by
co-immunoprecipitation analysis. We found that anti-Id2
and anti-E2F antibodies could pull down Rb from cell lysates
with or without TSA, and anti-Rb antibody could also pull
down E2F1 (Figure 3b). As expected, anti-phospho-Rb
antibody could not pull down E2F1 nor could anti-Id2 anti-
body pull down phospho-Rb (Figure 3b), which suggested
that phospho-Rb could not bind with Id2 and E2F1 in kidney
epithelial cells.
It has been reported that HDAC1 can form a trimeric
complex with Rb-E2F to repress gene expression.17,18 To test
for the presence of this complex, with or without TSA treat-
ment in Pkd1null/null MEK cells, we carried out co-immuno-
precipitation experiments. We found that HDAC1 could be
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Figure 1 | Trichostatin A (TSA) decreased the expression of inhibitor of differentiation 2 (Id2) but increased the expression of p21 in
Pkd1null/null mouse embryonic kidney (MEK) cells. (a) Western blot analysis of the expression of Id2, p21, and histone deacetylase (HDAC)
1 from whole-cell lysates of Pkd1 wild-type (WT) and Pkd1null/null MEK cells treated with or without TSA. The expression of Id2 was
decreased in Pkd1null/null MEK cells treated with TSA, whereas the expression of p21 was increased in Pkd1null/null MEK cells after TSA
treatment. The expression of Id2 and p21 with or without TSA treatment in MEK cells was quantified from three independent immunoblots
by densitometric analysis and was presented as a ratio of the band density of Id2 or p21 to actin. P value was marked in the graph
(bottom panels). The expression of HDAC1 was not affected by TSA treatment. (b) Western blot analysis of the expression of Id2 and p21
from whole-cell lysates of Pkd1null/null MEK cells treated with TSA at 0, 2, 4, 8, 12, and 24 h. Decreased expression of Id2 is accompanied
by increased expression of p21 in Pkd1null/null MEK cells.
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pulled down with anti-Rb antibody irrespective of whether
cells were treated with TSA (Figure 3c). However, phospho-
Rb could not be pulled down with anti-HDAC1 antibody.
PC1 affects the expression of Id2 in kidney epithelial cells
To exclude the possibility that the upregulation of Id2 in
Pkd1null/null MEK cells was being selected for or caused by
culturing under conditions that favor upregulation of Id2, we
performed the following two experiments. First, we knocked
down Pkd1 with either oligonucleotide-mediated siRNA
(Figure 4a) or lentiviral vector-mediated siRNA (Figure 4b)
in mouse inner medullary collecting duct cells and found that
these resulted in upregulation of Id2. We also found that
c-Myc was upregulated (Figure 4a). Second, when Pkd1 was
transfected back into Pkd1null/null MEK cells, it reduced the
expression of Id2 and c-Myc (Figure 4c). These experiments
suggested that the upregulation of Id2 in these cells was due
to the loss of Pkd1. As our anti-PC1 antibody could not
directly detect PC1 in western blotting analyses, we carried
out immunoprecipitation experiments with this anti-PC1
antibody, followed by western blotting to detect the presence
of PC1 (Figure 4a and c). We also evaluated the efficiency of
Pkd1 knockdown by RT-PCR (Figure 4a and b). It has
been reported that c-Myc could regulate the expression
of Id2.19,20 We further found that knockdown of c-Myc
with siRNA decreased the expression of Id2 in Pkd1 mutant
MEK cells (Figure 4d), which suggested that c-Myc was at
least one of the factors, together with HDACs, involved in
regulating the expression of Id2 in Pkd1 mutant kidney
epithelial cells.
TSA prevents cyst formation in Pkd1 mutant embryonic
kidneys
It has been reported that TSA treatment reduces the
progression of cyst formation in Pkd2 knockout mice.7
However, whether TSA can suppress cyst formation in Pkd1
knockout mice is unknown. To test this possibility, we
injected TSA into pregnant Pkd1m1Beiþ / female mice from
8.5 to 14.5 days postcoitus (d.p.c.). The embryonic kidneys
were then analyzed at 15.5 d.p.c. In all Pkd1m1Bei/ embryos
from TSA-injected mothers, kidney cyst formation was
significantly prevented or reduced compared with that from
dimethyl sulfoxide-injected mothers (Po0.05; Figure 5a–e).
Furthermore, we found that the expression of Id2 from the
TSA-treated Pkd1m1Bei/ embryonic kidneys was decreased
compared with that from the dimethyl sulfoxide-treated
Pkd1m1Bei/ embryonic kidneys (control) by western blot
analysis (Figure 5f) and by immunohistochemistry analysis
(Figure 5g, top panels). In contrast, the expression of Id2 was
increased in the cyst-lining epithelia without TSA treatment
by immunostaining with anti-Id2 antibody (Figure 5g,
bottom panels). We further found that double knockout
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Figure 2 | Inhibitor of differentiation 2 (Id2), but not histone deacetylase (HDAC) 1, regulates the expression of p21 in Pkd1null/null
mouse embryonic kidney (MEK) cells. (a) Transfection of small interfering RNA (siRNA) against Id2 into MEK cells inhibited Id2 expression
and also resulted in increased expression of p21 in Pkd1null/null MEK cells but not in Pkd1 wild-type (WT) MEK cells. The expression of p21
with or without knockdown Id2 with siRNA in MEK cells was quantified from three independent immunoblots by densitometric analysis
and was presented as a ratio of the band density of p21 to actin. P value was marked in the graph (right panels). (b) Chromatin
immunoprecipitation (ChIP) assay demonstrated that HDAC1 bound to the promoter region of p21 in MEK cells treated or untreated
with trichostatin A (TSA). Pkd1 WT and Pkd1null/null MEK cells were treated with or without TSA, and an anti-HDAC1 antibody was used
for ChIP analysis. PCR was performed using primers in the p21 promoter region as explained in Materials and Methods. Input is the
DNA template before ChIP. Binding of HDAC1 appeared to be reduced in samples of Pkd1 WT MEK cells treated with TSA compared
with samples of Pkd1null/null MEK cells. Anti-IgG was used as a negative control. (c) Transfection of siRNA against HDAC1 into MEK cells
inhibited HDAC1 expression but did not affect the expression of p21 in Pkd1 WT and Pkd1null/null MEK cells. IgG, immunoglobulin G.
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Id2 and Pkd1 also prevented cyst formation in E15.5
embryonic kidneys (Figure 5h), which strongly supported
the critical role of Id2 in this process.
DISCUSSION
Our study provides new insights into the mechanisms of
ADPKD by uncovering a network of HDAC signaling
through targeting Id2 and Id2-mediated downstream p21
and Rb–E2F pathways to modulate the proliferation of cystic
epithelial cells. We found that Id2 was upregulated in Pkd1
mutant and Pkd1 knockdown kidney epithelial cells. Our
fluorescence-activated cell sorting analysis suggested that
S-phase entry is significantly increased in Pkd1 mutant MEK
cells (Table 1). We propose that upregulated Id2 may increase
S-phase entry in Pkd1 mutant MEK cells (1) through binding
with Rb to control Rb-E2F-mediated S-phase entry; (2)
through binding with basic helix–loop–helix transcriptional
factors to inhibit transcription of the p21 gene; and (3)
through inhibition of p21 to increase Cdk2/Cdk4-mediated
phosphorylation of Rb, which will also release E2F from the
Rb–E2F complex to increase S-phase entry. We found that
HDACi decreased the expression of Id2 in Pkd1 mutant MEK
cells (Figure 1a). As such, HDACi might (1) free Rb from
Id2–Rb complexes, which would increase Rb–E2F1 complex
to decrease the E2F1-mediated S-phase entry; (2) release the
inhibition of Id2 on p21 gene transcription, which would
increase the expression of p21 (Figures 1a and 2a) and
decrease p21-mediated S-phase entry; and (3) through
increased p21 to decrease p21-Cdks-mediated phosphoryla-
tion of Rb (Figure 3a), which would also increase the
formation of Rb–E2F1 complex to decrease the E2F1-
mediated S-phase entry (summarized in Figure 6). This
study not only furthers our previous finding that PC2
interacts with Id2 in a PC1-dependent manner, sequestering
Id2 in the cytoplasm to regulate kidney epithelial cell
proliferation,13 but also provides the mechanism of HDACi
in preventing cyst formation in Pkd1 knockout mouse
models.7,8
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Figure 3 | Trichostatin A (TSA) targets the Rb–E2F pathway. (a) Retinoblastoma (Rb), phospho-Rb, and E2F1 are upregulated in
Pkd1null/null mouse embryonic kidney (MEK) cells. The expression of Rb, phospho-Rb, and E2F1 in Pkd1 wild-type (WT) and Pkd1null/null
MEK cells treated with or without TSA was analyzed by western blotting. The expression of Rb, phospho-Rb, and E2F1 were upregulated in
Pkd1null/null MEK cells compared with Pkd1 WT MEK cells untreated with TSA. After TSA treatment, phospho-Rb was decreased to the
same level seen in Pkd1 WT MEK cells either treated with or without TSA. The expression of phospho-Rb with or without TSA treatment in
MEK cells was quantified from three independent immunoblots by densitometric analysis and was presented as a ratio of the band density
of phospho-Rb to actin. P value was marked in the graph (bottom panel). (b) Co-immunoprecipitation assay indicated that Rb, but not
phospho-Rb, co-immunoprecipitated with inhibitor of differentiation 2 (Id2) and E2F1 in MEK cells treated or untreated with TSA.
Anti-Id2 antibody pull down Id2 always produced a doublet, whereas only the lower band represented Id2 as reported previously.13
(c) Co-immunoprecipitation assay indicated that only Rb, but not phospho-Rb, co-immunoprecipitated with histone deacetylase (HDAC) 1
in MEK cells treated or untreated with TSA. IP, immunoprecipitation; IB, immunoblotting.
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HDAC inhibitors have been found to repress cyst
formation in ADPKD mouse models.7,8 However, whether
HDACi functions by regulating cell proliferation to prevent
cyst formation, or functions by some other mechanisms, is
unknown. To identify the specific targets of HDACi in kidney
epithelial cell cycle regulation, we examined the expression of
p21 and its regulators, Id2 and HDAC1. HDAC1, through
binding to the p21 promoter, has been found to repress p21
expression in cancer cells.16 Id2, through binding to basic
HLH proteins, has also been found to regulate p21
expression.15 We found that the expression of p21 in
response to HDACi was correlated with expression of Id2,
but not HDAC1, in TSA-treated Pkd1 mutant MEK cells
(Figure 1b). TSA did not affect Id2 or p21 in Pkd1 wild-type
MEK cells. We then confirmed that Id2 was responsible for
regulation of p21 expression by Id2 siRNA knockdown
(Figure 2a). In addition, we excluded the possibility that
HDACi functions through HDAC1 to regulate p21 gene
expression in Pkd1null/null MEK cells by examining the effect
of TSA on binding of HDAC1 to the p21 promoter (Figure
2b) and by HDAC1 siRNA knockdown (Figure 2c). Thus, our
results indicate that Id2 is not only the target of HDACi but
also the key regulator of p21 expression in Pkd1 mutant
kidney epithelial cells, which suggests that HDACi may be
through targeting Id2–p21 pathway to regulate the cystic
epithelial cell cycle.
Id2 has also been reported to regulate cell proliferation
through the Rb–E2F pathway.15 Id2 can regulate the
formation or function of the Rb–E2F complex either by
directly binding with Rb or through p21-Cdks-mediated
phosphorylation of Rb, thus releasing E2F from the Rb–E2F
complex and allowing S-phase-specific genes to be tran-
scribed.15 We found that phospho-Rb was upregulated in
Pkd1null/null MEK cells and that TSA decreased the upregu-
lated phospho-Rb to levels seen in wild-type MEK cells
(Figure 3a). In addition, the upregulated Id2 and Rb appear
to be bound to each other (Figure 3b), which would also
release E2F from the inhibition of Rb. The decreased
expression of p21 in Pkd1 mutant MEK cells would be
expected to decrease its inhibition of Cdks, and might be
responsible for increasing phospho-Rb, releasing E2F from
the Rb–E2F complex (Figure 6).
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Figure 4 |Polycystin-1 (PC1) affects the expression of inhibitor of differentiation 2 (Id2) in kidney epithelial cells. (a) Transfection of
small interfering RNA (siRNA) against PC1 into mouse inner medullary collecting duct (IMCD) cells inhibited PC1 expression and resulted in
upregulation of Id2 and c-Myc. The expression of PC1 was detected by immunoprecipitation and then immunoblotting analysis with an
anti-PC1 antibody and also examined by RT-PCR. (b) PC1 expression was also knocked down by the constitutive expression of specific anti-
Pkd1 siRNA mediated by a puromycin-selectable lentiviral vector, VIRHD/P/siPKD13297, which strongly increased the expression of Id2
compared with the control VIRHD/P/siLuc lentivector-transduced cells. Mouse IMCD3 cells were transduced with VIRHD/P/siPKD13297 or the
control VIRHD/P/siLuc lentivector, in which the Pkd1 siRNA was replaced by the anti-luciferase siRNA.24 PC1 expression in VIRHD/P/
siPKD13297 was reduced by more than 90% when compared with the transduced control VIRHD/P/siLuc lentivector, as assayed by reverse
transcription-PCR (bottom panels). (c) Transient transfection of Pkd1 into Pkd1null/null mouse embryonic kidney (MEK) cells reduced the
expression of Id2 and c-Myc. The expression of PC1 was detected by immunoprecipitation and then by immunoblotting analysis with an
anti-PC1 antibody. (d) Transfection of siRNA against c-Myc into Pkd1 mutant MEK cells inhibited c-Myc expression and resulted in
downregulation of Id2.
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Many of the genes that are required for DNA synthesis
contain E2F sites in their promoters. Transcription from
promoters containing E2F sites can be actively repressed
by a trimeric complex containing E2F, Rb, and HDAC1 or
HDAC2.17,18,21 Before the G1–S transition, phosphorylation of
Rb leads to dissociation of the E2F–Rb–HDAC repressor
complex. E2F is then free to activate transcription by con-
tacting basal factors or histone acetyltransferases, such as
CREB-binding protein, which can alter chromatin structure.
We found that HDAC1 interacts with Rb but not phospho-Rb
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Figure 5 | Treatment with trichostatin A (TSA) prevents cyst formation in Pkd1m1Bei–/– embryonic kidneys. (a–d) Representative
histological sections of E15.5 Pkd1þ /þ and Pkd1m1Bei–/– embryonic kidneys from pregnant mothers injected with TSA or control vehicle
(dimethyl sulfoxide, DMSO) from 8.5 to 14.5 d.p.c. (a) Pkd1þ /þ from TSA-treated mother; (b) Pkd1þ /þ from DMSO-treated mother;
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of cystic areas over total kidney section areas of Pkd1 wild-type (WT) and Pkd1m1Bei–/– treated with or without TSA. The middle section of
each kidney was quantified for all mice under each condition. Shown are mean and s.e.m. of all sections quantified for each condition.
Treatment with TSA significantly prevents cyst formation in Pkd1m1Bei–/– embryonic kidneys compared with the control to the left (Po0.05).
(f) Western blot analysis of the expression of inhibitor of differentiation 2 (Id2) from Pkd1þ /þ (WT) or Pkd1m1Bei–/– embryonic kidneys
treated with or without TSA. The expression levels of Id2 were decreased in Pkd1m1Bei–/– embryonic kidneys treated with TSA.
(g) Immunohistochemistry (top panel) and immunostaining (bottom panel) analyses of the expression of Id2 from Pkd1þ /þ or Pkd1m1Bei–/–
embryonic kidneys treated with DMSO or TSA. (h) Knockout of Id2 rescues renal cystic phenotype in Pkd1null/null mutants. Id2-Pkd1 double
knockout (KO) and Id2þ /þ :Pkd1null/null embryonic kidneys are displayed.
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in Pkd1 wild-type and Pkd1null/null MEK cells, either treated
with TSA or untreated (Figure 3c). These results suggested that
although HDAC1 may not be involved in regulating the
expression of p21 in these cells, it may still be involved in
regulating other genes through the Rb–E2F pathway (Figure 6).
In the current working model, we also provided evidence
to support a causative role for PC1 in regulating the
expression of Id2 in kidney epithelial cells through Pkd1
knockdown and rescue experiments (Figure 4). In our
previous study, we found that Id2 expression was upregulated
in the kidney of ADPKD patients, but we did not find a
significant difference in Id2 expression between Pkd1 wild-
type and mutant MEK cells.13 However, in this study, we
found that Id2 was upregulated in Pkd1 mutant MEK cells.
The different cell growth conditions might be the cause of
this difference. In particular, all MEK cells used in this study
were synchronized by serum starvation and then refed with
serum for further analysis.
Our results and the published evidence suggested that
c-Myc together with HDACs was involved in regulating the
expression of Id2 in kidney epithelial cells. It has been found
that in ADPKD, renal c-Myc expression is consistently
elevated up to 15-fold.22 c-Myc has also been shown to
regulate the expression of Id2,19,20 and together with HDACs
has been shown to regulate the transcription of a number of
genes.23 We found that when Pkd1 was knocked down
with its siRNA, the expression of c-Myc was upregulated,
and when Pkd1 was transiently transfected back into Pkd1
mutant MEK cells, the expression of c-Myc was down-
regulated (Figure 4). We further found that knockdown of
c-Myc with siRNA decreased the expression of Id2 in Pkd1
mutant MEK cells (Figure 4d), which suggested that c-Myc
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binding with basic helix–loop–helix (bHLH) transcriptional factors to inhibit transcription of the p21 gene; and/or (3) through inhibition of
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complex to decrease the E2F1-mediated S-phase entry; (2) release the inhibition of Id2 on p21 gene transcription, which would increase the
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was at least one of the factors, together with HDACs, involved
in regulating the expression of Id2 in Pkd1 mutant kidney
epithelial cells.
Valproic acid, the class I HDAC inhibitor, was found to
repress cyst formation in Pkd1 conditional knockout mice.8
These results suggest that class I HDACs are involved in
regulating cystogenesis. Although the expression of class I
HDACs was not changed, valproic acid might affect the
activity of class I HDAC, such as HDAC1, to regulate the
pathway(s) downstream of it, such as HDAC1-Rb-E2F in
some way as we presented in the current model (Figure 6).
However, this possibility needs to be further investigated.
In this study, we found that the pan-HDAC inhibitor,
TSA, prevented cyst formation in vivo in Pkd1 knockout
embryonic kidneys (Figure 5), very possibly due to targeting
Id2 and Id2-mediated p21 and Rb–E2F pathways. Id2 and
Pkd1 double knockout prevented cyst formation and further
supported the central role of Id2 in this process (Figure 5h).
As such, our findings provide mechanism of HDACi in
preventing cyst formation in Pkd1 knockout mouse model
and further support the hypothesis that HDAC inhibitors are
potential therapeutic agents for the treatment of ADPKD.
MATERIALS AND METHODS
Cell culture and cell cycle analysis
Pkd1 wild-type and Pkd1null/null MEK cells were maintained as
described previously.13 For cell cycle analysis, MEK cells were
synchronized by serum starvation for 24 h, followed by addition of
2% serum with or without TSA for 48 h, stained with propidium
iodide, and analyzed by fluorescence-activated cell sorting. For
all other analysis, MEK cells were also synchronized by serum
starvation for 24 h, followed by refeeding with 2% serum.
Immunoprecipitation and western blotting
Immunoprecipitation and western blotting were performed on
whole-cell lysates as described by the manufacturer (Upstate
Biotechnology, Lake Placid, NY). The antibodies used for western
blotting included anti-Id2 (c-20), p21 (F-5), E2F1 (c-20), Rb (c-15),
and PC1 (H260) antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA); anti-HDAC1 antibodies (Upstate-Millipore, Lake Placid, NY);
anti-actin, anti-tubulin, and anti-acetyl-tubulin antibodies (Sigma,
St Louis, MO); and anti-phospho-Rb (Cell Signaling Technology,
Beverly, MA). All primary antibodies were used at 1:50 for
immunoprecipitation and 1:500 for western blotting. Donkey
anti-rabbit immunoglobulin G (IgG)-horseradish peroxidase and
Donkey anti-mouse IgG-horseradish peroxidase (1:8000 dilution,
Santa Cruz) were used as secondary antibodies for western blotting.
Chromtin immunoprecipitation
Chromatin was prepared from Pkd1 wild-type and Pkd1null/null MEK
cells treated with or without TSA for 24 h according to the
manufacturer’s instructions (Upsate), with a crosslinking time of
15 min at 25 1C and sonication to an average length of 200–700 bp.
Chromatin immunoprecipitation was performed using an anti-
HDAC1 monoclonal antibody (Upstate Biotechnology). Samples were
analyzed by PCR. The following primers for p21 were used: forward,
50-TGCGTGACAAGAGAATAGCCCAG-30 and reverse, 50-TGCAGTT
GGCGTCGAGCTGC-30.
RNA interference
The oligonucleotides used for mouse Id2, HDAC1, and PC1 RNA
interference were purchased from Thermo Dharmacon (Lafayette,
CO). The oligonucleotides used for mouse c-Myc were purchased
from Santa Cruz. The oligonucleotides were transfected using the
DharmaFECT siRNA transfection reagent (Dharmacon). Cells were
harvested and protein expression was analyzed by western blotting.
PC1 expression was also knocked down by the constitutive
expression of specific anti-Pkd1 siRNA mediated by a puromycin-
selectable lentiviral vector, VIRHD/P/siPKD13297 (kindly provided
by Dr G Luca Gusella, Albert Einstein College of Medicine).
Mouse inner medullary collecting duct 3 cells were transduced with
VIRHD/P/siPKD13297 or the control VIRHD/P/siLuc lentivector, in
which the Pkd1 siRNA was replaced by the anti-luciferase siRNA.24
Following 2 days of puromycin selection (3 days post-transduction),
the IMCD/P/siLuc and IMCD/P/siPKD13297 cells were derived for
further analysis.
Mouse strain and treatment
To obtain embryos of various genotypes, heterozygous mutant mice
were paired and pregnant females were killed on 15.5 d.p.c. to collect
embryonic kidneys. For TSA treatment experiments, pregnant
Pkd1m1Beiþ /– females paired with Pkd1m1Beiþ /– males were sub-
cutaneously injected daily, from 8.5 to 14.5 d.p.c., with 0.5 mg TSA
(Sigma) per gram mouse body weight or with an equal volume
of the vehicle dimethyl sulfoxide. To obtain embryos of Pkd1
and Id2 double knockout, we crossed Pkd1þ /nullId2þ / females
with Pkd1þ /nullId2þ / males and pregnant females were killed
on 15.5 d.p.c. to collect embryonic kidneys. At the end of this
treatment, females were killed and embryonic kidneys were collected
and fixed in 4% paraformaldehyde. Genomic DNA from the
embryos was obtained (XNAT Extract-N-Amp Tissue PCR Kit,
Sigma) and genotyped (JumpStart Kit, Sigma).
Statistic analysis
Data are presented as mean±s.e.m. The significance of differences
between groups was examined by an unpaired Student’s t-test or
a one-way ANOVA with Prism 4.0 software (GraphPad Software,
San Diego, CA), followed by a Newman–Keuls post hoc test. A
P-value o0.05 is considered significant.
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